Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy-Reference-Cited by-同舟云学术

Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy

Published:2015-05-12 Issue:11 Volume:56 Page:3116-3123
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Qin Ya-Zhen,Xu Lan-Ping,Chen Huan,Jiang Qian,Wang Yu,Jiang Hao,Zhang Xiao-Hui,Han Wei,Chen Yu-Hong,Wang Feng-Rong,Wang Jing-Zhi,Zhu Hong-Hu,Liu Yan-Rong,Jiang Bin,Liu Kai-Yan,Huang Xiao-Jun

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1032964

Reference33 articles.

1. Fusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia

2. Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

3. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup

4. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ZNF384 fusion transcript levels for measurable residual disease monitoring in adult B‐cell acute lymphoblastic leukemia;Hematological Oncology;2024-01

2. Comparison of efficacy between homoharringtonine, aclarubicin, cytarabine (HAA) and idarubicin, cytarabine (IA) regimens as induction therapy in patients with de novo core binding factor acute myeloid leukemia;Annals of Hematology;2023-08-12

3. Combination of KIT and FLT3‐ ITD mutation status with minimal residual disease levels guides treatment strategy for adult patients with inv(16) acute myeloid leukemia in first complete remission;Hematological Oncology;2022-05-15

4. Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes;Blood Cancer Journal;2021-12

5. How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring;Biomedicines;2021-08-03